Champignon Brands’ Canadian Rapid Treatment Center of Excellence Opens First Community-Based Centre in Ottawa to Provide Ketamine Treatment for Adults With Depression Jan 25 • 4 min read Champignon Brands Inc. (SHRM) (FWB: 496) (OTCQB: SHRMF), Chairman and CEO Roger McIntyre today announced the opening of a new Canadian Rapid Treatment Center of Excellence (CRTCE) clinic in Ottawa, Ontario. This third clinic joins the Mississauga and Toronto clinics (CRTCE Clinics) in addressing the unmet need of depression and suicide through novel ketamine therapy treatment.
PharmaTher Signs License Agreement for Patented Ketamine Treatment Jan 22 • 3 min read PharmaTher has entered an agreement with the National Health Research Institutes of Taiwan to develop and commercialize a patented formulation of FDA-approved ketamine and betaine combination called KETABET.
Mydecine Innovations Group Included in First-Ever Psychedelics ETF Jan 22 • 3 min read Mydecine Innovations Group has been included in the first-ever Psychedelics Exchanged Traded Fund (ETF).
Revive Therapeutics Announces $10 Million Bought Deal Offering of Units Jan 21 • 5 min read Revive Therapeutics Ltd. announced that is has entered into an agreement with underwriters have agreed to purchase 20,000,000 units at a price of $0.50 per equity unit for gross proceeds to the company of $10,000,000.
MindMed Announces the Start of the First-Ever Clinical Trial Combining MDMA and LSD Jan 20 • 4 min read MindMed announced today the start of the first ever clinical trial measuring and evaluating MDMA and LSD used in combination in the human body.